Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models

MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Hyo-jeong, Moon, Hyun-ki, Lee, Junho, Yang, Gi-hyeok, Yang, Sung-yoon, Yun, Hwi-yeol, Chae, Jung-woo, Kang, Won-ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308925/
https://www.ncbi.nlm.nih.gov/pubmed/34358080
http://dx.doi.org/10.3390/ph14070654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308925/
https://www.ncbi.nlm.nih.gov/pubmed/34358080
http://dx.doi.org/10.3390/ph14070654

Ejemplares similares